Attached files
| file | filename |
|---|---|
| EX-99.2 - EX-99.2 - OPKO HEALTH, INC. | d290117dex992.htm |
| EX-99.1 - EX-99.1 - OPKO HEALTH, INC. | d290117dex991.htm |
| EX-23.1 - EX-23.1 - OPKO HEALTH, INC. | d290117dex231.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 29, 2011
OPKO Health, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-33528 | 75-2402409 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
4400 Biscayne Blvd
Miami, Florida 33137
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (305) 575-4100
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
EXPLANATORY NOTE
OPKO Health, Inc. (the “Company”) is filing this Amendment No. 1 to its Current Report on Form 8-K that was initially filed with the Securities and Exchange Commission on December 29, 2011, to file the financial statements and pro forma information required by Item 9.01 of Form 8-K with respect to the Company’s acquisition of FineTech Pharmaceutical Ltd.
| ITEM 9.01. | Financial Statements and Exhibits |
(a) Financial Statements of Businesses Acquired.
The following financial statements of FineTech Pharmaceutical Ltd. are being filed with this report as Exhibit 99.1:
| • | Audited Balance Sheet as of December 31, 2010 |
| • | Audited Statement of Operations for the year ended December 31, 2010 |
| • | Audited Statement of Shareholder’s Equity |
| • | Audited Statement of Cash Flows for the year ended December 31, 2010 |
| • | Unaudited Balance Sheet as of September 30, 2011 |
| • | Unaudited Statements of Operations for the nine months ended September 30, 2011 and September 30, 2010 |
| • | Unaudited Statement of Shareholder’s Equity as of September 30, 2011 |
| • | Unaudited Statements of Cash Flows for the nine months ended September 30, 2011 and September 30, 2010 |
(b) Pro Forma Financial Information.
The following pro forma financial information is being filed with this report as Exhibit 99.2:
| • | Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 30, 2011 |
| • | Unaudited Pro Forma Condensed Consolidated Statement of Operations for the nine months ended September 30, 2011 |
| • | Unaudited Pro Forma Condensed Consolidated Statement of Operations for the year ended December 31, 2010 |
(d) Exhibits
| Exhibit Number |
Description | |
| 23.1 | Consent of Kost Forer Gabby and Kasierer, A Member of Ernst & Young Global | |
| 99.1 | Financial Statements listed in Item 9.01(a) | |
| 99.2 | Pro Forma Financial Information listed in Item 9.01(b) | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OPKO Health, Inc. | ||||
| By | /s/ Rao Uppaluri | |||
| Name: | Rao Uppaluri | |||
| Title: | Senior Vice President, Chief Financial Officer | |||
Date January 25, 2012
Exhibit Index
| Exhibit |
Description | |
| 23.1 | Consent of Kost Forer Gabby and Kasierer, A Member of Ernst & Young Global | |
| 99.1 | Financial Statements listed in Item 9.01(a) | |
| 99.2 | Pro Forma Financial Information listed in Item 9.01(b) | |